Review



dir umibio  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress dir umibio
    In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of <t>Cy7.7</t> -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).
    Dir Umibio, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 48 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dir+umibio/pmc12955658-107-20-22?v=MedChemExpress
    Average 95 stars, based on 48 article reviews
    dir umibio - by Bioz Stars, 2026-07
    95/100 stars

    Images

    1) Product Images from "GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma"

    Article Title: GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma

    Journal: International Journal of Pharmaceutics: X

    doi: 10.1016/j.ijpx.2026.100510

    In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of Cy7.7 -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).
    Figure Legend Snippet: In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of Cy7.7 -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).

    Techniques Used: In Vivo, Injection, Fluorescence, Imaging, Labeling, Ex Vivo, Immunohistochemical staining, Staining, Control



    Similar Products

    dir umibio  (MedChemExpress)
    95
    MedChemExpress dir umibio
    In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of <t>Cy7.7</t> -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).
    Dir Umibio, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dir+umibio/pmc12955658-107-20-22?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    dir umibio - by Bioz Stars, 2026-07
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of Cy7.7 -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).

    Journal: International Journal of Pharmaceutics: X

    Article Title: GPC3 and CD133-targeted peptide dual modification enhances the therapeutic effect of doxorubicin carried by OMVs on hepatocellular carcinoma

    doi: 10.1016/j.ijpx.2026.100510

    Figure Lengend Snippet: In vivo antitumor efficacy and biodistribution of SsnB-pretreated and dual-targeted OMVs@DOX in a murine hepatoma model. (A) Schematic illustration of the experimental timeline and treatment groups ( n = 5). Mice received SsnB pretreatment followed by intravenous injection of: 1) PBS; 2) Blank OMVs; 3) Free DOX; 4) GPC3ᵀ-OMVs@DOX; 5) CD133ᵀ-OMVs@DOX; 6) (GPC3 + CD133)ᵀ-OMVs@DOX. (B) In vivo fluorescence imaging showing the biodistribution of Cy7.7 -labeled OMVs in tumor-bearing mice post-injection. (C) Ex vivo fluorescence imaging of dissected major organs and tumors at 24 h post-injection. # # #p < 0.001, # # p < 0.01, and # p < 0.05 vs. Oil/DMSO+SpC-OMVs group. (D) Tumor volume growth curves of mice during the treatment period. (E) Body weight curves of mice during the treatment period. (F) Representative photographs and weights of excised tumors at the endpoint of the study. (G) Immunohistochemical staining of Ki-67 in tumor tissues, showing proliferation index across treatment groups. Scale bar: 50 μm. Data are presented as mean ± SD (n = 5).Statistical significance is denoted as follows: #, compared to the control group (Oil/DMSO + SpC-OMVs); *, compared between treatment groups (#/* p < 0.05, ##/** p < 0.01, ###/*** p < 0.001,).

    Article Snippet: To detect the metabolism of OMVs in vivo, different types of OMVs were labeled with DiR (UR21017, Umibio, China) or Cy7 (HY-D0825, MedChemExpress, USA).

    Techniques: In Vivo, Injection, Fluorescence, Imaging, Labeling, Ex Vivo, Immunohistochemical staining, Staining, Control